Piedmont participating in expanded Access for COVID-19 treatments

Press release from Piedmont Walton

Atlanta (June 10, 2020) – Piedmont Healthcare, in a continuing effort to bring the latest and most innovative treatments to its patients, is participating in U.S. Food and Drug Administration (FDA) expanded access programs to treat COVID-19 through the use of convalescent plasma and nitric oxide. Patients at Piedmont Walton are also eligible for these programs, according to officials with Piedmont Healthcare.

FDA expanded access programs, sometimes called “compassionate use,” represent a process by which patients with immediately life-threatening conditions or a serious disease can gain access to an investigational medical product for treatment outside of clinical trials when no comparable or alternative therapy options are available.

The convalescent plasma program is being run through the Mayo Clinic, to which Piedmont will report back its data. The convalescent plasma program involves the donation of plasma, the liquid portion of the blood, from COVID-19 survivors and possesses antibodies. Antibodies are the protein the body uses to fight infections. The Red Cross is one organization that is receiving donations of plasma from those who have recovered from COVID-19 and then donating them to Piedmont patients who are part of the program. This program is available at all Piedmont hospitals.

In addition, Piedmont also is exploring the use of nitric oxide for hospitalized COVID-19 positive patients who are not on a ventilator. As part of this protocol, the patient’s oxygen is mixed with nitric oxide in the hope that it will help to open the patient’s airways to improve oxygen levels in the blood. This program is available at Piedmont Atlanta Hospital and at Piedmont Fayette Hospital.

Regarding COVID-19 research, Piedmont is participating in clinical trials for the anti-inflammatory drug gimsilumab and one that studies proning, or repositioning patients to improve oxygen levels.

“We are working our hardest to bring the latest treatments to our patients during the pandemic,” said Amy Hajari Case, M.D., Piedmont’s Medical Director of Pulmonary and Critical Care Research. “Clinical research is playing an important role in the treatment of patients who are positive for COVID-19 and it is our hope that these programs will help to reduce the disease’s mortality and shorten the hospital stays for others.”

To learn more about these trials, please visit https://www.piedmont.org/research/research-home.

About Piedmont Healthcare

Piedmont Healthcare empowers communities to connect with safe and high-quality care, conveniently, every step of the way. Our promise is to make a positive difference in every life we touch and today we are creating a destination known for the best clinicians and a safe one-of-a-kind experience that always puts patients first. Founded in 1905, we are a private, not-for-profit organization with over 23,000 employees caring for 2.7 million patients across 800 locations and serving communities that comprise 70 percent of Georgia’s population. Piedmont provides safe, convenient and high-quality care across 11 hospitals, 34 Piedmont Urgent Care centers, 28 QuickCare locations, 555 Piedmont Clinic physician practice locations and more than 2,500 Piedmont Clinic members. In 2019, Forbes listed us as one of the Top10 Employers in Georgia, Piedmont became Great Place to Work-Certified™, which was repeated in 2020, and is the safest health care system in Georgia. In FY 2019, Piedmont provided $340 million in uncompensated care and community benefit programming to the communities we serve. For more information, visit piedmont.org.



Be the first to comment

Leave a Reply